Holen Sie sich die Stockscreener-App
4.18
1.65%
-0.07
Handel nachbörslich:
3.88
-0.30
-7.18%
Schlusskurs vom Vortag:
$4.25
Offen:
$4.2
24-Stunden-Volumen:
216.10K
Relative Volume:
0.14
Marktkapitalisierung:
$3.62M
Einnahmen:
$9.81M
Nettoeinkommen (Verlust:
$-26.16M
KGV:
-0.1078
EPS:
-38.77
Netto-Cashflow:
$-17.45M
1W Leistung:
-14.87%
1M Leistung:
-62.43%
6M Leistung:
-96.63%
1J Leistung:
-98.77%
1-Tages-Spanne:
$4.11
$4.3154
1-Wochen-Bereich:
$4.03
$8.29
52-Wochen-Spanne:
$4.03
$414.99
Reshape Lifesciences Inc Stock (RSLS) Company Profile
Firmenname
Reshape Lifesciences Inc
Sektor
Branche
Telefon
949-429-6680
Adresse
1001 CALLE AMANECER, SAN CLEMENTE
Vergleichen Sie RSLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
4.18 | 3.62M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Reshape Lifesciences Inc Aktie (RSLS) Neueste Nachrichten
SEC Form 424B3 filed by ReShape Lifesciences Inc. - Quantisnow
ReShape Lifesciences achieves EU and UK medical device certification By Investing.com - Investing.com South Africa
ReShape Lifesciences And Kiora Pharma Impress Investors, Dollar General Uplifts Outlook - Finimize
Why ReShape Lifesciences Stock Is Soaring Today: Key Drivers Behind Weight-Loss Company's Surge - Benzinga
ReShape Lifesciences Receives EU Certification for Product Portfolio; Shares Jump - marketscreener.com
ReShape Lifesciences Stock Soars On Regulatory Certification For Medical Devices In EU, UK: Retail Eyes Fair Valuation - Asianet Newsable
ReShape Lifesciences Stock Soars On Regulatory Certification For Medical Devices In EU, UK: Retail Eyes Fair Valuation By Stocktwits - Investing.com India
ReShape Lifesciences (RSLS) Stock Skyrockets Over 62% in Morning Trading Frenzy - Daily Chhattisgarh News
ReShape Lifesciences achieves EU and UK medical device certification - Investing.com India
ReShape Lifesciences (RSLS) Achieves Key European and UK Certifications | RSLS Stock News - GuruFocus
ReShape Lifesciences Achieves EU MDR and UKCA Certification for Medical Devices, Enhancing Patient Safety and Market Access in Europe - Nasdaq
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio - GlobeNewswire
ReShape Lifesciences Beats 2027 Deadline: Gains Crucial EU MDR Certification While Others Still Wait - Stock Titan
RSLS stock touches 52-week low at $4.03 amid market challenges By Investing.com - Investing.com South Africa
RSLS stock touches 52-week low at $4.03 amid market challenges - Investing.com India
ReShape Lifesciences Faces Nasdaq Delisting Notice - TipRanks
ReShape Lifesciences Announces Equity Distribution Agreement - TipRanks
ReShape Lifesciences announces merger progress By Investing.com - Investing.com South Africa
ReShape Lifesciences Announces Merger with Vyome Therapeutics - TipRanks
ReShape Lifesciences announces merger progress - Investing.com
ReShape Lifesciences (NASDAQ:RSLS) Raised to Hold at Wall Street Zen - Defense World
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update - GlobeNewswire
RSLS stock touches 52-week low at $5.5 amid market challenges - Investing.com
ReShape Lifesciences reports Q1 EPS $18.98 vs. ($135.37) last year - TipRanks
ReShape Lifesciences (RSLS) Reports Q1 Revenue Drop and Highlights Strategic Advances | RSLS Stock News - GuruFocus
ReShape Lifesciences Inc. Reports First Quarter 2025 Financial Results and Strategic Updates - Nasdaq
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
ReShape Reports 43% Revenue Drop While Advancing Merger Deal and Securing Key Patents - Stock Titan
ReShape Lifesciences Inc. SEC 10-Q Report - TradingView
ReShape Lifesciences Delays 10-Q Filing - TipRanks
Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter - MSN
Reshape Lifesciences Inc Files For Mixed Shelf Offering Of Up To $50 MillionSEC Filing - marketscreener.com
ReShape Lifesciences Announces Reverse Stock Split - TipRanks
ReShape Lifesciences announces 1-for-25 reverse stock split By Investing.com - Investing.com Canada
ReShape Lifesciences (RSLS) Announces 1-for-25 Reverse Stock Spl - GuruFocus
ReShape Lifesciences announces 1-for-25 reverse stock split - Investing.com Australia
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split - The Manila Times
ReShape Lifesciences Inc. Announces 1-for-25 Reverse Stock Split Effective May 9, 2025 - Nasdaq
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The MergerALBT, NDOI, DNB, RSLS - The Malaysian Reserve
ReShape Lifesciences (RSLS) Secures Patent for Innovative Intrag - GuruFocus
RSLSReshape Lifesciences Inc. Latest Stock News & Market Updates - Stock Titan
ReShape Lifesciences (RSLS) Showcases Promising Diabetes Device at Neuromodulation Event | RSLS Stock News - GuruFocus
ReShape Lifesciences® Unveils Innovative Diabetes Neuromodulation Device Demonstrating Safe Glucose Modulation at Minnesota Neuromodulation Symposium - Nasdaq
ReShape Lifesciences® Presents Pre-clinical Data on Its - GlobeNewswire
Breakthrough Diabetes Treatment: New Neuromodulation Device Eliminates Need for Insulin Injections - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – ALBT, NDOI, DNB, RSLS - GlobeNewswire Inc.
The Psychology of ReShape Lifesciences Inc Inc. (RSLS) Price Performance: Understanding Market Sentiment - investchronicle.com
Finanzdaten der Reshape Lifesciences Inc-Aktie (RSLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.56%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):